Get the Daily Brief
Latest Biotech News
Nuclear CDK Activation in Cell Division Initiates in the Nucleus, Not Cytoplasm
Contrary to prevailing models, recent research reveals that cyclin-dependent kinase (CDK) activation triggering mitosis occurs primarily within the cell nucleus rather than at cytoplasmic...
AI Model ProtoBind-Diff Enables Drug-Like Molecule Design from Protein Sequences
Gero has introduced ProtoBind-Diff, a masked diffusion language model that generates novel drug-like molecules conditioned solely on protein amino acid sequences, foregoing the need for structural...
TTYH2 and APOE Interaction Illuminates Endosomal Lipid Transfer Mechanisms
Structural biology studies employing cryo-electron microscopy and biochemical reconstitution have revealed how the membrane protein TTYH2 interacts with disc-shaped APOE-containing lipoprotein...
AI Enhances Breast Cancer Detection with Largest Open-Source MRI Dataset
Researchers from The City College of New York and Memorial Sloan Kettering Cancer Center developed an interpretable deep learning model achieving high accuracy in detecting and localizing breast...
Open-Source Robotic Exoskeleton Framework Unveiled for Mobility Assistance
Northern Arizona University researchers have introduced OpenExo, an open-source robotic exoskeleton framework designed to facilitate the development of mobility-assisting devices. By providing...
Kymera’s Strategic Shakeup: Gilead Partnership and Sanofi Shift
Kymera Therapeutics is recalibrating its development strategy with a new partnership with Gilead Sciences to co-develop oral molecular glue degraders targeting CDK2, an enzyme associated with...
AlphaGenome: Google’s AI Advances Gene Regulation Prediction
DeepMind’s latest AI model, AlphaGenome, offers a pioneering approach to predicting the effects of DNA sequence variations on gene regulation. Unlike protein structure predictions by AlphaFold,...
Revolution Medicines Secures $2B to Propel RAS(ON) Inhibitors Globally
Revolution Medicines acquired up to $2 billion through a flexible funding deal with Royalty Pharma, enhancing their financial runway to internally develop and commercialize RAS(ON) inhibitors...
AI Enhances Cancer Cell Diversity Profiling for Precision Therapy
A collaborative multinational team has developed an advanced AI-based framework, AAnet, to characterize intratumoral heterogeneity in cancers with unprecedented detail by analyzing single-cell...
Ionis and Biogen Advance Next-Gen SMA Therapy Salanersen
Ionis Pharmaceuticals and Biogen reported encouraging Phase 1 results for salanersen, a potent antisense oligonucleotide developed for spinal muscular atrophy (SMA) that builds on the mechanism of...
FDA Investigates Sarepta’s Duchenne Gene Therapy After Patient Deaths
Following two patient deaths linked to acute liver failure shortly after treatment with Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys, the FDA has begun reviewing the therapy's...
Breakthroughs in Mitochondrial Base Editing Offer Hope for Genetic Disease
Researchers at University Medical Center Utrecht and colleagues have achieved precision mitochondrial base editing to correct pathogenic mitochondrial DNA mutations in patient-derived cells....
City of Hope Launches Generative AI Platform to Transform Cancer Care
City of Hope unveiled HopeLLM, a proprietary generative AI platform integrating multiple AI models with extensive oncology datasets to streamline clinical workflows and research. The application...
New Epigenomic Tools Illuminate Drug Mechanisms and Target Discovery
Foghorn Therapeutics’ Senior Director Dave Lahr highlights advances in epigenomic methods—CUT&RUN, ATAC-seq, and bisulfite sequencing—that enable high-resolution chromatin profiling to elucidate...
Kymera’s reshaped alliances: Gilead pact amid Sanofi shuffle
Kymera Therapeutics announced a significant licensing deal with Gilead Sciences to develop oral molecular glue degraders targeting proteins implicated in breast cancer. This partnership could...
FDA investigates Sarepta’s Elevidys after patient fatalities
Following two recent patient deaths caused by acute liver failure, the FDA has launched an investigation into Sarepta Therapeutics' gene therapy Elevidys for Duchenne muscular dystrophy. The...
Lilly’s tirzepatide to dominate GLP-1 drug market by 2030
Evaluate reports that total prescription drug sales are projected to reach $1.75 trillion by 2030, with GLP-1 receptor agonists constituting 9% of prescriptions. Eli Lilly's tirzepatide is...
Bristol Myers faces fresh antitrust suit over Pomalyst exclusivity
Bristol Myers Squibb is embroiled in a new 203-page antitrust lawsuit filed by insurance company Cigna, alleging BMS employed illegal tactics to preserve its monopoly on the multiple myeloma drug...
AI model AlphaGenome predicts gene regulation from DNA alterations
DeepMind introduced AlphaGenome, a comprehensive AI model designed to predict the effects of small DNA mutations on gene regulation and molecular processes. This marks an advance beyond protein...
Gene therapy mitochondrial base editing corrects pathogenic mutations
Researchers have successfully applied mitochondrial base editing (mtBE) to correct harmful mutations in mitochondrial DNA within patient-derived cells. Employing the DdCBE system, a...